Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesStephen D. Wiviott, Marc S. Sabatine, Itamar Raz et al.|New England Journal of Medicine|2018Cited by 6.3k
Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeGregory G. Schwartz, Andreas M. Zeiher, Philippe Gabríel Steg et al.|New England Journal of Medicine|2018Cited by 3.5k
Cardiovascular Risk Reduction with Icosapent Ethyl for HypertriglyceridemiaDeepak L. Bhatt, Christie M. Ballantyne, Philippe Gabríel Steg et al.|New England Journal of Medicine|2018Cited by 3.2k
A Controlled Trial of Renal Denervation for Resistant HypertensionDeepak L. Bhatt, George L. Bakris, David E. Kandzari et al.|New England Journal of Medicine|2014Cited by 2.2k
Long-Term Use of Ticagrelor in Patients with Prior Myocardial InfarctionMarc P. Bonaca, Marc S. Sabatine, Deepak L. Bhatt et al.|New England Journal of Medicine|2015Cited by 2k